Palm Beach, FL 6/26/12 (StreetBeat) -- Supernus Pharmaceuticals Inc (Nasdaq: SUPN) said the U.S. health regulator granted a tentative approval to its epilepsy treatment Trokendi XR, sending its shares up 38 percent before the bell.
The company said the U.S. Food and Drug Administration completed a review of Trokendi, an extended release version of Johnson & Johnson's widely-used epilepsy drug Topamax, and did not seek any additional clinical trials.
Topamax is off patent protection and is available generically.
Supernus said the final approval of its drug depended on resolving a marketing exclusivity issue raised by the FDA regarding a specific pediatric population.
Shares of Supernus were trading at $7.75 in premarket trade. They closed at $5.71 on Monday on the Nasdaq.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail firstname.lastname@example.org or call (662) 392-0740 for pricing and scheduling.